東北大学加齢医学研究所　臨床腫瘍学分野　東北大学　腫瘍内科

研究室紹介

HOME < 研究業績 < 英文論文 2022年度

英文論文 2022年度

  1. Yoshioka T，Takahashi M，Sakamoto Y，Okita A，Fukui T，Murakawa Y，Shindo Y，Imai H，Ohori H，Shirota H，Chiba N，Sasahara Y I，Nomura T，Fukushima N，Yamaguchi T，Shimodaira H，Ishioka C. Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial. Anticancer Res 42. 2009-2015. Apr（2022）
  2. Shimizu D，Takahashi M，Mizutani T. Interpretation of the Efficacy of Multidisciplinary Geriatric Assessment Intervention on Chemotherapy-Related Toxic Effects in Older Adults With Cancer. JAMA Oncol 8. 1.Apr 1（2022）
  3. Kikuchi K，Yamazaki N，Nozawa K，Fukuda H，Shibata T，Machida R，Hamaguchi T，Takashima A，Shoji H，Boku N，Takatsuka S，Takenouchi T，Nishina T，Yoshikawa S，Takahashi M，Hasegawa A，Kawazoe A，Masuishi T，Mizutani H，Kiyohara Y. Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part). Support Care Cancer 30. 4497-4504.May（2022）
  4. Osumi H，Ouchi K，Shinozaki E，Takahashi S，Ooki A，Nakayama I，Wakatsuki T，Ogura M，Takahari D，Chin K，Yamaguchi K，Ishioka C. Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer. Int J Colorectal Dis 37. 1439-1447. Jun（2022）
  5. Yoshida S，Sato F，Tagami K，Sasaki R，Takahashi C，Sasaki K，Takahashi S. Development of the opioid self-management scale for advanced Cancer patients with pain and examination of its validity and reliability. BMC Palliat Care 21. 102. Jun 6（2022）
  6. Katoh Y，Yaguchi T，Kubo A，Iwata T，Morii K，Kato D，Ohta S，Satomi R，Yamamoto Y，Oyamada Y，Ouchi K，Takahashi S，Ishioka C，Matoba R，Suematsu M，Kawakami Y. Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. J Immunother Cancer 10.Jul（2022）
  7. Yamaguchi K，Minashi K，Sakai D，Nishina T，Omuro Y，Tsuda M，Iwagami S，Kawakami H，Esaki T，Sugimoto N，Oshima T，Kato K，Amagai K，Hosaka H，Komine K，Yasui H，Negoro Y，Ishido K，Tsushima T，Han S，Shiratori S，Takami T，Shitara K. Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer. Cancer Sci 113. 2814-2827.Aug（2022）
  8. Okada M，Kato K，Cho B C，Takahashi M，Lin C-Y，Chin K，Kadowaki S，Ahn M-J，Hamamoto Y，Doki Y，Yen C-C，Kubota Y，Kim S-B，Hsu C-H，Holtved E，Xynos I，Matsumura Y，Takazawa A，Kitagawa Y. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). Clin Cancer Res 28. 3277-3286.Aug 2（2022）
  9. Chiba Y，Sudo K，Kojima Y，Okuma H，Kohsaka S，Machida R，Ichimura M，Anjo K，Kurishita K，Okita N，Nakamura K，Kinoshita I，Takahashi M，Matsubara J，Kusaba H，Yonemori K，Takahashi M. A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial. BMC Cancer 22. 869.Aug 9（2022）
  10. Saijo K，Imai H，Katayama H，Fujishima F，Nakamura K，Kasahara Y，Ouchi K，Komine K，Shirota H，Takahashi M，Ishioka C. BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation. Case Reports in Oncology 2022 15. 762-769.Aug 30（2022）
  11. Otsuki Y，Ouchi K，Takahashi S，Sasaki K，Sakamoto Y，Okita A，Ishioka C. Altered gene expression due to aberrant DNA methylation correlates with responsiveness to anti-EGFR antibody treatment. Cancer Sci 113. 3221-3233.Sep（2022）
  12. Osumi H，Ishizuka N，Takashima A，Kumekawa Y，Nakano D，Shiozawa M，Denda T，Sawada R，Ouchi K，Wakatsuki T，Narikazu B，Kato K，Yamaguchi K，Shinozaki E. Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol. BMJ Open 12. e063071.Sep 1（2022）
  13. Kambayashi Y，Kasahara Y，Ohuchi K，Amagai R，Hashimoto A，Asano Y，Fujimura T. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate. Dermatol Ther 35. e15736.Oct（2022）
  14. Imai M，Nakamura Y，Sunami K，Kage H，Komine K，Koyama T，Amano T，Ennishi D，Kanai M，Kenmotsu H，Maeda T，Morita S，Sakai D，Bando H，Makiyama A，Suzuki T，Hirata M，Kohsaka S，Tsuchihara K，Naito Y，Yoshino T. Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors. Cancer Sci 113. 3646-3656.Nov（2022）
  15. Sunami K，Naito Y，Komine K，Amano T，Ennishi D，Imai M，Kage H，Kanai M，Kenmotsu H，Koyama T，Maeda T，Morita S，Sakai D，Kohsaka S，Tsuchihara K，Saigusa Y，Yoshino T. Chronological improvement in precision oncology implementation in Japan. Cancer Sci 113. 3995-4000.Nov（2022）
  16. Qi H，Kikuchi M，Yoshino Y，Fang Z，Ohashi K，Gotoh T，Ideta R，Ui A，Endo S，Otsuka K，Shindo N，Gonda K，Ishioka C，Miki Y，Iwabuchi T，Chiba N. BRCA1 transports the DNA damage signal for CDDP-induced centrosome amplification through the centrosomal Aurora A. Cancer Sci 113. 4230-4243.Dec（2022）
  17. Takahashi S，Oridate N，Tanaka K，Shimizu Y，Fujimoto Y，Matsumoto K，Yokota T，Yamazaki T，Takahashi M，Ueda T，Hanai N，Yamaguchi H，Hara H，Yoshizaki T，Yasumatsu R，Nakayama M，Shiga K，Fujii T，Mitsugi K，Takahashi K，Nohata N，Gumuscu B，Swaby R F，Tahara M. First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048. Int J Clin Oncol 27. 1805-1817.Dec（2022）
  18. Naito Y，Sunami K，Kage H，Komine K，Amano T，Imai M，Koyama T，Ennishi D，Kanai M，Kenmotsu H，Maeda T，Morita S，Sakai D，Watanabe K，Shirota H，Kinoshita I，Yoshioka M，Mamesaya N，Ito M，Kohsaka S，Saigusa Y，Yamamoto K，Hirata M，Tsuchihara K，Yoshino T. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan. JAMA Netw Open 5. e2245081.Dec 1（2022）
  19. Watanabe H，Fujishima F，Motoi T，Aoyama Y，Niihori T，Takahashi M，Umegaki S，Oishi H，Tada H，Ichinohasama R，Sasano H. Comprehensive genomic profiling of a unique liposarcoma arising in a patient with Li-Fraumeni syndrome and the novel detection of c-myc amplification: a case report. Diagn Pathol 17. 93. Dec 13（2022）
  20. Kawamura M，Shirota H，Niihori T，Komine K，Takahashi M，Takahashi S，Miyauchi E，Niizuma H，Kikuchi A，Tada H，Shimada M，Kawamorita N，Kanamori M，Sugiyama I，Tsubata M，Ichikawa H，Yasuda J，Furukawa T，Aoki Y，Ishioka C. Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility. J Hum Genet Feb 20（2023）
  21. Shirota H，Komine K，Takahashi M，Takahashi S，Miyauchi E，Niizuma H，Tada H，Shimada M，Niihori T，Aoki Y，Sugiyama I，Kawamura M，Yasuda J，Suzuki S，Iwaya T，Saito M，Saito T，Shibata H，Furukawa T，Ishioka C. Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study. Cancer Med 12. 6170-6181.Mar（2023）
  22. Endo M，Kataoka T，Fujiwara T，Tsukushi S，Takahashi M，Kobayashi E，Yamada Y，Tanaka T，Nezu Y，Hiraga H，Wasa J，Nagano A，Nakano K，Nakayama R，Hamada T，Kawano M，Torigoe T，Sakamoto A，Asanuma K，Morii T，Machida R，Sekino Y，Fukuda H，Oda Y，Ozaki T，Tanaka K. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib. BMC Cancer 23. 219.Mar 8（2023）
  23. Sasaki K，Takahashi S，Ouchi K，Otsuki Y，Wakayama S，Ishioka C. Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types. Sci Rep 13. 4868.Mar 24（2023）

ページの先頭へ戻る

© 2006 Department of Medical Oncology, Tohoku University Hospital All rights reserved.